Paras Biopharmaceuticals Wins International Award
Paras Biopharmaceuticals wins the 2014 European Biopharmaceuticals Technology Innovation Leadership Award by Frost & Sullivan.
Oulu, Finland, December 11, 2014 --(PR.com)-- Paras Biopharmaceuticals Finland Oy, a Finnish company based in Oulu has been recognized by Frost & Sullivan with the “2014 European Biopharmaceuticals Technology Innovation Leadership Award” for biopharmaceutical technology development.
Paras Biopharmaceuticals has built a robust portfolio of proprietary technologies for the production of therapeutic biomedicines for osteoporosis and diabetes. The Finnish company has developed innovative solutions for the effective and economic production of recombinant therapeutics.
Each year, Frost & Sullivan presents the Award for Technology Innovation Leadership (Europe) to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the high R&D quality towards innovation, its relevance to the industry and the positive impact on brand perception.
Paras Biopharmaceuticals has successfully developed three proprietary manufacturing technologies: Diabrid® Technology, NobleCleav® Technology and Biomultifold® Microbial High Expression Technology for the development of several biopharma active pharmaceuticals ingredients (APIs), targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), and oncology.
Diabrid® Technology works as a critical enabler for achieving the correct target product, NobleCleav® Technology facilitates the high-level production of authentic biologics by combining specificity and activity of processing of recombinant therapeutic peptides and proteins, while the Biomultifold® Microbial High Expression Technology helps to achieve expression levels of multigrams of therapeutic proteins per litre of fermentation using E.coli.
“In a time of widespread economic austerity, demand for access to affordable healthcare is greater than ever,” says Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals. “This award by Frost & Sullivan recognises Paras Biopharmaceuticals’ hard work and commitment in developing more economical and efficient technologies for the production of biosimilars and noble biologics.”
“Paras Biopharmaceuticals has developed proprietary expression vectors based on the most optimum genetic codes selected for each amino acid of the therapeutic,” said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “Genes are coupled with suitable Diabrid® partners to achieve a unique combination of therapeutic proteins and peptides.”
“The company not only possesses exceptional process development skills to achieve the highest levels of protein expression, but also has extensive experience in protein purification,” noted Chidambaram. “Its core strengths, ranging from media selection and development, optimization of process parameters, screening of resins to minimizing aggregation concepts in purification have earned the company a reputation for being an important innovator in biopharmaceuticals.”
About Paras Biopharmaceuticals
Paras Biopharmaceuticals Finland Oy is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Paras’ state-of-the-art European GMP US-FDA compliant production set-up facilitates scale-up technologies and products for clinical and commercial manufacturing.
Paras’ work revolves around two main streams
· Biosimilars comprised of osteoporosis recombinant Teriparatide, analog insulin and therapeutic fragment of monoclonal antibodies
· High value recombinant enzymes such as Enterokinase (and other enzymes in pipeline).
About Frost & Sullivan
Frost & Sullivan is a Growth Partnership Company that works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. Its Growth Partnership supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure. For more than 50 years, Frost & Sullivan have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Paras Biopharmaceuticals has built a robust portfolio of proprietary technologies for the production of therapeutic biomedicines for osteoporosis and diabetes. The Finnish company has developed innovative solutions for the effective and economic production of recombinant therapeutics.
Each year, Frost & Sullivan presents the Award for Technology Innovation Leadership (Europe) to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the high R&D quality towards innovation, its relevance to the industry and the positive impact on brand perception.
Paras Biopharmaceuticals has successfully developed three proprietary manufacturing technologies: Diabrid® Technology, NobleCleav® Technology and Biomultifold® Microbial High Expression Technology for the development of several biopharma active pharmaceuticals ingredients (APIs), targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), and oncology.
Diabrid® Technology works as a critical enabler for achieving the correct target product, NobleCleav® Technology facilitates the high-level production of authentic biologics by combining specificity and activity of processing of recombinant therapeutic peptides and proteins, while the Biomultifold® Microbial High Expression Technology helps to achieve expression levels of multigrams of therapeutic proteins per litre of fermentation using E.coli.
“In a time of widespread economic austerity, demand for access to affordable healthcare is greater than ever,” says Dr. Hans Soderlund, Director of Global Strategic Alliance at Paras Biopharmaceuticals. “This award by Frost & Sullivan recognises Paras Biopharmaceuticals’ hard work and commitment in developing more economical and efficient technologies for the production of biosimilars and noble biologics.”
“Paras Biopharmaceuticals has developed proprietary expression vectors based on the most optimum genetic codes selected for each amino acid of the therapeutic,” said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “Genes are coupled with suitable Diabrid® partners to achieve a unique combination of therapeutic proteins and peptides.”
“The company not only possesses exceptional process development skills to achieve the highest levels of protein expression, but also has extensive experience in protein purification,” noted Chidambaram. “Its core strengths, ranging from media selection and development, optimization of process parameters, screening of resins to minimizing aggregation concepts in purification have earned the company a reputation for being an important innovator in biopharmaceuticals.”
About Paras Biopharmaceuticals
Paras Biopharmaceuticals Finland Oy is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Paras’ state-of-the-art European GMP US-FDA compliant production set-up facilitates scale-up technologies and products for clinical and commercial manufacturing.
Paras’ work revolves around two main streams
· Biosimilars comprised of osteoporosis recombinant Teriparatide, analog insulin and therapeutic fragment of monoclonal antibodies
· High value recombinant enzymes such as Enterokinase (and other enzymes in pipeline).
About Frost & Sullivan
Frost & Sullivan is a Growth Partnership Company that works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. Its Growth Partnership supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure. For more than 50 years, Frost & Sullivan have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community.
Contact
Paras Biopharmaceuticals Finland Oy
Dr Mark Jackson
+358442905993
www.parasbiopharma.com
Dr Mark Jackson
+358442905993
www.parasbiopharma.com
Contact
Categories